Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
First Generics of Equa Priced at 30% of Original Product
The first generics of the DPP-4 inhibitor Equa (vildagliptin) hit the Japan market on December 6 in conjunction with their reimbursement listing on the day, with the nine products by nine companies all priced at 30.4% of the brand-name version.…
To read the full story
Related Article
- Espha/Bayer Unit Add Pediatric Indication to Xarelto AG
December 11, 2025
- Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
- Xarelto Copycats Earn Blessing, AG Might also Get on Board
August 19, 2024
- Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
BUSINESS
- Pfizer Targets Double-Digit Oncology Growth in Japan over Next 5 Years
December 16, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…